Monday, September 8, 2025

PharmaTher Sponsors Research For Novel Delivery Of Ketamine

PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into a sponsored research agreement. The agreement, which was signed with The Queen’s University of Belfast, will see the development of a patented hydrogel-forming microneedle patch for use with ketamine.

More specifically, the microneedle patch is being developed to work with KETABET, PharmaTher’s proprietary formulation for ketamine. The patch is being viewed as a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders, while limiting the potential for abuse and misuse. Microneedle delivery has the potential to overcome drawbacks associated with introvenous or nasal delivery methods.

The research is being led by Professor Ryan Donnelly, whom most recently published a paper on ketamine related to using a microneedle array as a delivery method. The MN tech, as the firm refers to it, is expected to overcome limitations related to drug quantities on the patch, while also improving the quantity of the drug that can permeate into the skin from the patch.

“We believe that ketamine and our proprietary ketamine formulation, KETABET™, delivered in the patented microneedle patch could potentially change the ways that mental health, neurodegenerative and pain disorders are treated.  We are pursuing the clinical development of KETABET™ MN patch to overcome the current limitations of ketamine and to unlock the known potential therapeutic value of ketamine as a prescription for regulatory approval worldwide.”

Fabio Chianelli, CEO of PharmaTher

The company is currently focused on developing a patch for FDA approval, which ultimately overcomes drawbacks related to other methods of delivery.

PharmaTher last traded at $0.22 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

Related News

PharmaDrug JV Submits Application For Phase 1 Clinical Trials In Australia

PharmaDrug Inc (CSE: DRUG) has seen one of its joint ventures advance to the clinical...
Wednesday, May 15, 2024, 09:17:48 AM

PharmaTher Files With FDA For Pre-IND Meeting On Use Of Ketamine In Treatment Of Parkinson’s Disease

PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a pre-investigational new drug...

Tuesday, December 8, 2020, 09:08:04 AM

Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research

Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research...

Wednesday, November 18, 2020, 07:30:40 AM

PharmaTher Files Patent Application In US For Psilocybin Drug Combination To Treat Neurological Disorders

PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a provisional patent application...

Tuesday, December 15, 2020, 09:00:13 AM

Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli

Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down...

Tuesday, November 24, 2020, 01:00:00 PM